Technoven Competitors

RadNet, Inc. is the largest U.S. provider of freestanding outpatient diagnostic imaging services, operating over 400 centers across key markets, including Arizona, California, Florida, and New York. In addition to imaging, RadNet offers AI-driven solutions under the DeepHealth brand, radiology IT, and teleradiology services. With over 10,000 employees and affiliated radiologists, RadNet is dedicated to advancing healthcare through innovation and expertise.

Heartflow is the global leader in AI-driven coronary artery disease (CAD) management, transforming how CAD — the world’s leading cause of death — is diagnosed and treated. Our advanced technology generates personalized, precision 3D heart models from a single CT scan, providing clinicians with the clarity and confidence to deliver earlier, more effective treatments — transforming CAD into a disease that can be managed for life. Heartflow One is the only complete, non-invasive, precision coronary care platform providing patient insights throughout the guideline-directed coronary CTA pathway. The AI-driven platform — including Roadmap™ Analysis, FFRct Analysis and Plaque Analysis — is supported by ACC/AHA guidelines and backed by more than 625 peer-reviewed publications. With over 650,000 patients treated, more than 1,800 leading institutions adopting our solution, and 99.5% of U.S. lives covered — Heartflow is redefining the standard of coronary care. We're a global company, with employees across the United States, Europe and Japan. Our headquarters are in San Francisco, California, with additional offices in California, Texas, the UK and Japan. We believe CAD shouldn’t be a silent threat. We’re changing the story of CAD by making it screenable, diagnosable, and manageable — empowering clinicians to save lives and giving patients more time for what matters most.

Lunit is a leading provider of AI solutions for cancer diagnostics and therapeutics, with a mission to conquer cancer through AI. Our clinically proven AI enables healthcare providers to detect cancer earlier, make more precise treatment decisions, and improve patient outcomes — transforming how cancer is diagnosed and treated. Our technology spans the entire cancer continuum, from risk prediction and screening optimization to early detection and precision oncology. Lunit’s breast and chest imaging AI boosts diagnostic accuracy and efficiency, while our pathology AI is leveraged by leading pharmaceutical companies to drive biomarker discovery and companion diagnostics (CDx) development. Trusted by 10,000+ sites across 65+ countries, Lunit continues to redefine global standards in data-driven cancer care. Learn more about our technology and mission at www.lunit.io/en